New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection
- 10 December 2020
- journal article
- review article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 34 (1)
- https://doi.org/10.1111/dth.14660
Abstract
Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL‐23/IL‐17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.Keywords
This publication has 55 references indexed in Scilit:
- Cutaneous and visceral leishmaniasis during anti-TNFα therapyWiener Medizinische Wochenschrift, 2016
- The microbiota and immune response during Clostridium difficile infectionAnaerobe, 2016
- Klebsiella pneumoniae: Going on the Offense with a Strong DefenseMicrobiology and Molecular Biology Reviews, 2016
- Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective AnalysisPediatric Dermatology, 2016
- Serious infections in hospitalized patients with psoriasis in the United StatesJournal of the American Academy of Dermatology, 2016
- The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational CohortsThe Journal of Rheumatology, 2016
- Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated DiseasesAnnual Review of Medicine, 2016
- Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive PatientsMediators of Inflammation, 2015
- Behavioral and Socioeconomic Risk Factors Associated with Probable Resistance to Ceftriaxone and Resistance to Penicillin and Tetracycline in Neisseria gonorrhoeae in ShanghaiPLOS ONE, 2014
- Clostridium difficile: A European perspectiveJournal of Infection, 2013